TBPH insider Form 4 shows tax withholding, 308,762 shares owned

Rhea-AI Filing Summary

Theravance Biopharma, Inc. reported an insider equity transaction by a senior officer. On 11/20/2025, 9,060 ordinary shares were withheld at $17.90 per share to cover tax obligations from the vesting of previously granted restricted stock units. The explanation states that this share withholding was with the issuer and did not involve any open market transaction. Following this tax-related transaction, the officer directly beneficially owns 308,762 ordinary shares of Theravance Biopharma.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Farnum Rhonda

Role SVP, COMM & MEDICAL AFFAIRS

Type	Security	Shares	Price	Value
Tax Withholding	Ordinary Shares	9,060	$17.90	$162K

Holdings After Transaction: Ordinary Shares — 308,762 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Farnum Rhonda

(Last) (First) (Middle)

C/O THERAVANCE BIOPHARMA US, LLC

901 GATEWAY BLVD

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Theravance Biopharma, Inc. [ TBPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, COMM & MEDICAL AFFAIRS

3. Date of Earliest Transaction (Month/Day/Year)
11/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	11/20/2025		F		9,060(1)	D	$17.9	308,762	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.

	/s/ Corinna Liebowitz, Attorney-in-Fact	11/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Theravance Biopharma (TBPH) report on this Form 4?

Theravance Biopharma reported a tax withholding transaction in which 9,060 ordinary shares were withheld from a senior officer on 11/20/2025 in connection with the vesting of restricted stock units.

What was the price used for the 9,060 TBPH shares withheld?

The Form 4 states that 9,060 ordinary shares were withheld at a price of $17.90 per share to satisfy tax obligations related to vested restricted stock units.

How many Theravance Biopharma (TBPH) shares does the officer own after the transaction?

After the reported transaction, the Form 4 shows that the officer beneficially owns 308,762 ordinary shares of Theravance Biopharma, held directly.

What is the transaction code for the TBPH Form 4 insider transaction?

The Form 4 lists the transaction code as “F”, which indicates shares were withheld by the issuer to pay tax obligations arising from equity award vesting.

Did the Theravance Biopharma insider sell shares on the open market?

The explanation notes that the share withholding was with the issuer and did not involve an open market transaction; it was solely to satisfy tax obligations from RSU vesting.

What is the reporting person’s role at Theravance Biopharma (TBPH)?

The filing identifies the reporting person as an officer serving as SVP, Commercial & Medical Affairs of Theravance Biopharma.